89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24 2020 - 8:00AM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced that Rohan Palekar,
the company’s Chief Executive Officer, will participate in 1x1
meetings with investors at the Piper Sandler 32nd Annual Virtual
Healthcare Conference on Wednesday, December 2, 2020. The
conference will take place December 1-3, 2020. An archived webcast
of the fireside chat is accessible in the investor section of
89bio’s website.
About 89bio89bio is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of innovative therapies for the treatment of
liver and cardio-metabolic diseases. The company’s lead product
candidate, BIO89-100, is a specifically engineered glycoPEGylated
analog of FGF21. BIO89-100 is being developed for the treatment of
nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia
(SHTG). 89bio is headquartered in San Francisco with operations in
Herzliya, Israel.
Investor Contact:Ryan MartinsChief Financial
Officerinvestors@89bio.com
Media Contact:Peter
Duckler773-343-3069pduckler@w2ogroup.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Sep 2023 to Sep 2024
